These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 35269990)

  • 1. Stem Cell Therapy: From Idea to Clinical Practice.
    Mousaei Ghasroldasht M; Seok J; Park HS; Liakath Ali FB; Al-Hendy A
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies.
    Ratcliffe E; Glen KE; Naing MW; Williams DJ
    Br Med Bull; 2013; 108():73-94. PubMed ID: 24200742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
    Witten CM; McFarland RD; Simek SL
    Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Innovative, Comprehensive Mapping and Multiscale Analysis of Registered Trials for Stem Cell-Based Regenerative Medicine.
    Monsarrat P; Vergnes JN; Planat-Bénard V; Ravaud P; Kémoun P; Sensebé L; Casteilla L
    Stem Cells Transl Med; 2016 Jun; 5(6):826-35. PubMed ID: 27075765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hurdles to clinical translation of human induced pluripotent stem cells.
    Neofytou E; O'Brien CG; Couture LA; Wu JC
    J Clin Invest; 2015 Jul; 125(7):2551-7. PubMed ID: 26132109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Path Forward for Regenerative Medicine.
    Fanaroff AC; Morrow V; Krucoff MW; Seltzer JH; Perin EC; Taylor DA; Miller LW; Zeiher AM; Fernández-Avilés F; Losordo DW; Henry TD; Povsic TJ
    Circ Res; 2018 Aug; 123(4):495-505. PubMed ID: 30355250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving regulatory landscape in regenerative medicine.
    Beetler DJ; Di Florio DN; Law EW; Groen CM; Windebank AJ; Peterson QP; Fairweather D
    Mol Aspects Med; 2023 Jun; 91():101138. PubMed ID: 36050142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders.
    Richardson E; Akkas F; Master Z
    Regen Med; 2020 Jul; 15(7):1825-1832. PubMed ID: 32815780
    [No Abstract]   [Full Text] [Related]  

  • 13. Concise review: Adipose-derived stem cells as a novel tool for future regenerative medicine.
    Mizuno H; Tobita M; Uysal AC
    Stem Cells; 2012 May; 30(5):804-10. PubMed ID: 22415904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
    Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
    Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA regulation of adult stem cell therapies as used in sports medicine.
    Chirba MA; Sweetapple B; Hannon CP; Anderson JA
    J Knee Surg; 2015 Feb; 28(1):55-62. PubMed ID: 25603042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies.
    Kimbrel EA; Lanza R
    Regen Med; 2015; 10(2):99-102. PubMed ID: 25835474
    [No Abstract]   [Full Text] [Related]  

  • 19. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Between the Local and the Global:
    Hauskeller C
    Perspect Biol Med; 2018; 61(1):42-58. PubMed ID: 29805147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.